Tag: structure

DUBLIN, June 02, 2026 (GLOBE NEWSWIRE) --

Tyrur Holdings Unlimited Company, a global Irish strategic advisory firm founded in 2016 with an international advisory footprint connected to over EUR 5 billion in client-related assets, has established a strategic framework with UBS in Switzerland, marking an important step in the Firm’s continued expansion across global capital markets, institutional financial infrastructure, and cross-border advisory services.

GARDENA, California, June 02, 2026 (GLOBE NEWSWIRE) -- Polar Power, Inc. (“Polar Power” or the “Company”) (NASDAQ: POLA), a global provider of prime, backup and solar hybrid DC power solutions, today highlighted its financial results for its first quarter ended March 31, 2026, which the Company disclosed by its quarterly report on Form 10-Q with the Securities and Exchange Commission on May 20, 2026, and its recent operational progress. The quarter reflected substantial year-over-year gains in gross margin, operating results, and balance sheet strength, supported by a $3.7 million sales order backlog as of March 31, 2026.

REYNOLDSBURG, Ohio, June 02, 2026 (GLOBE NEWSWIRE) -- Victoria’s Secret & Co. (“VS&Co” or the “Company”) (NYSE: VSXY) today reported financial results for the first quarter ended May 2, 2026.

BELGRADE, Serbia, June 02, 2026 (GLOBE NEWSWIRE) -- International crypto entertainment platform 1win has officially announced the signing of the full Tundra Esports Dota 2 roster. Effective June 1, professional players Pure, bzm, 33, Ari, and Whitemon compete under the 1win Team tag. Alongside the players, coach MoonMeander, esports analyst degaz, team manager Jamba, and sports director SweetyPotz are joining the organization.

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　 announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.